ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019
Patient-Perceived Lack of Choice in Receipt of Radioactive Iodine for Treatment of Differentiated Thyroid Cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06980103 (Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer: The Radiance Trial
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2025Guideline
- Patient Perspectives Toward a Decision Aid for Radioactive Iodine Treatment for Intermediate Risk Thyroid Cancer.International journal of behavioral medicine · 2025Article
- Decision Variables for the Use of Radioactive Iodine in Patients with Thyroid Cancer at Intermediate Risk of Recurrence.Cancers · 2024Review
- Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors.Cellular and molecular life sciences : CMLS · 2024Article
- Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis.The Journal of clinical endocrinology and metabolism · 2023Review
- Change in worry over time among Hispanic women with thyroid cancer.Journal of cancer survivorship : research and practice · 2022Article
- Disparities in Thyroid Care.Endocrinology and metabolism clinics of North America · 2022Review
- Radioactive iodine therapy: multiple faces of the same polyhedron.Archives of endocrinology and metabolism · 2022Review
- Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.Frontiers in endocrinology · 2022Article
- Identification of immune-related ferroptosis prognostic marker and in-depth bioinformatics exploration of multi-omics mechanisms in thyroid cancer.Frontiers in molecular biosciences · 2022Article
- Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study.Thyroid : official journal of the American Thyroid Association · 2021Article
- Physician management of thyroid cancer patients' worry.Journal of cancer survivorship : research and practice · 2021Article
- Management of thyroid cancer: results from a German and French patient survey.Hormones (Athens, Greece) · 2021Article
- Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2021Article
- Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2021Article
- Removal of Radioactive Iodine Using Silver/Iron Oxide Composite Nanoadsorbents.Nanomaterials (Basel, Switzerland) · 2021Article
- Thyroid cancer patients satisfaction at the management outcome: an analysis of the results of a nationwide survey in 485 subjects.BMC health services research · 2021Article
- Thyroid Cancer Patients' View of Clinician Professionalism and Multidisciplinary Approach to Their Management.Journal of multidisciplinary healthcare · 2021Article
- Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer.Journal of cancer survivorship : research and practice · 2020Article
- The Year in Medical Thyroidology Review: Current Challenges and Future Directions.Thyroid : official journal of the American Thyroid Association · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
purposeFor many patients with differentiated thyroid cancer, use of radioactive iodine (RAI) does not improve survival or reduce recurrence risk. Yet there is wide variation in RAI use, emphasizing the importance of understanding patient perspectives regarding RAI decision making. PATIENTS AND
methodsAll eligible patients diagnosed with thyroid cancer from 2014 to 2015 from the Georgia and Los Angeles SEER registries were surveyed (N = 2,632; response rate, 63%). Patients in whom selective RAI use is recommended were included in this analysis (n = 1,319). Patients were asked whether they felt like they had a choice to receive RAI (yes or no), how strongly their physician recommended RAI (5-point Likert-type scale), whether they received RAI (yes or no), and how satisfied they were with their RAI decision (more [score of 4 or greater]
resultsMore than half of respondents (55.8%) perceived they did not have an RAI choice, and the majority of patients (75.9%) received RAI. The odds of perceiving no RAI choice was greater among those whose physician strongly recommended RAI (adjusted odds ratio [OR], 1.56; 95% CI, 1.13 to 2.17). Patients who perceived they did not have an RAI choice were more likely to receive RAI (adjusted OR, 2.50; 95% CI, 1.64 to 3.82) and report lower decision satisfaction (adjusted OR, 2.31; 95% CI, 1.67 to 3.20).
conclusionMany patients did not feel they had a choice about whether to receive RAI. Patients who perceived they did not have a choice were more likely to receive RAI and report lower decision satisfaction, suggesting a need for more shared decision making to reduce overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.